BMO-MRW best predictor of progression

Article

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a new study.

When detecting and evaluating the progression of glaucoma, Bruch's membrane opening-minimum rim width (BRO-MRW) may be the best predictor of the threshold of visual sensitivity and total deviation of visual field, according to a study published in Clinical Ophthalmology.

Japanese researchers examined the association between structural parameters of the optic nerve head and glaucomatous visual field indices in a total of 57 eyes in 33 patients with glaucomatous optic neuropathy.

The researchers measured the patients' visual fields, peripapillary retinal nerve fibre layer thickness (RNFL-T), BMO-MRW, and rim area. They then calculated Spearman's rank correlation coefficients between the threshold of visual sensitivity or total deviation of visual field and between the structural parameters as well as calculated RNFL-T and BMO-MRW volumes (each length multiplied by rim area).

They found that the threshold of visual sensitivity had the following correlation coefficients:

  • 0.23 with global sector of RNFL-T
  • 0.32 with BMO-MRW
  • 0.14 with rim area
  • 0.21 with RNFL-T volume
  • 0.26 with BMO-MRW volume

The correlation coefficients for each parameter with total deviation of visual field were as follows:

  • 0.22 with global sector of RNFL-T
  • 0.33 with BMO-MRW
  • 0.28 with rim area
  • 0.36 with RNFL-T volume
  • 0.37 with BMO-MRW volume

"Our study data confirm that total deviation was more strongly correlated with RNFL-T volume and BMO-MRW volume than with BMO-MRW. However, BMO-MRW appeared to be the best predictor of both the threshold of visual sensitivity and total deviation of visual field, and may be more useful for detecting and evaluating the progression of glaucoma," the researchers wrote.

To access the full article, click here.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.